Shanghai, China

Lingyun Wu

This inventor holds 27 USPTO granted patents and 9 published patent applications, plus 6 CIPO patents and 21 EPO patents. Top assignees: Medshine Discovery Inc., Guangdong Raynovent Biotech Co., Ltd., Helioeast Science & Technology Co., Ltd.. Active years: 2017-2026.

USPTO Granted Patents = 27 

% Patents Active = 96.3

 

 

Average Co-Inventor Count = 5.8

ph-index = 2

Forward Citations = 29(Granted Patents)


Company Filing History:

goldMedal10 out of 71 
 
Medshine Discovery Inc.
 patents
silverMedal3 out of 13 
 
Guangdong Raynovent Biotech Co., Ltd.
 patents
bronzeMedal2 out of 2 
 
Helioeast Science & Technology Co., Ltd.
 patents
41 out of 121 
 
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 patents
51 out of 2 
 
China Resources Pharmaceutical Holdings Company Limited
 patents
61 out of 32 
 
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
 patents
71 out of 5 
 
Guangdong Zhongsheng Pharmaceutical Co., Ltd
 patents
81 out of 3 
 
Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd.
 patents
91 out of 1 
 
Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd.
 patent
101 out of 1 
 
Guizhou Inochini Technology Co., Ltd
 patent
111 out of 1 
 
Helioeast Pharmaceutical Co., Ltd
 patent
121 out of 1 
 
Helioeast Pharmaceutical Co., Ltd.
 patent
131 out of 1 
 
Helioeast Science & Technology Co., Ltd.
 patent
141 out of 18 
 
Jiangsu Kanion Pharmaceutical Co., Ltd.
 patents
151 out of 2 
 
Jumbo Drug Bank Co., Ltd.
 patents
161 out of 40 
 
Merck Canada Inc.
 patents
171 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
181 out of 1 
 
Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.
 patent
191 out of 3 
 
Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.
 patents
where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...
Loading Chart...
Loading Chart...
27 patents (USPTO):Explore Patents

Title: An Overview of Inventor Lingyun Wu and His Contributions to Patents

Introduction: Lingyun Wu is a prominent inventor based in Shanghai, China, renowned for his significant contributions in the field of biochemistry and pharmaceuticals. With a total of 20 patents to his name, Wu has positioned himself as a key figure in the development of innovative compounds aimed at addressing various medical conditions.

Latest Patents: Two of Wu's latest inventions highlight his commitment to advancing medical science. The first patent, titled "Salt of LSD1 Inhibitor and a Polymorph Thereof," details a compound known as compound III, which serves as an inhibitor of LSD1. This invention is crucial in the preparation of medicaments designed to treat diseases related to LSD1. The second patent focuses on "Benzo 2-azaspiro[4.4]nonane Compound and Use Thereof," which discloses a range of benzo 2-azaspiro[4.4]nonane compounds, particularly emphasizing a compound represented by formula (P) and its pharmaceutically acceptable salts.

Career Highlights: Throughout his career, Lingyun Wu has made remarkable strides in the pharmaceutical industry. His work has been instrumental in the creation of novel therapeutic substances, enhancing medical treatment options for various conditions. Wu's entrepreneurial skill, combined with his scientific expertise, has led to the advancement of innovative solutions in the healthcare sector.

Collaborations: Wu has collaborated with notable colleagues such as Shuhui Chen and Jian Li, contributing to a dynamic research environment that fosters innovation and development. His associations with leading companies like Medshine Discovery Inc. and Guangdong Raynovent Biotech Co., Ltd. further exemplify his commitment to collaborative research and development in pharmaceuticals.

Conclusion: Lingyun Wu is a distinguished inventor whose innovative work has resulted in a notable portfolio of patents that contribute to advancements in medical science. His dedication to researching and developing new compounds continues to inspire and pave the way for future innovations in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…